Monte Rosa Therapeutics (GLUE) Change in Acquisitions & Divestments (2022 - 2026)

Monte Rosa Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $72.9 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 85.08% year-over-year to $72.9 million; the TTM figure through Mar 2026 stood at $313.0 million (up 93.28% YoY), while the FY2025 annual figure was $279.5 million, up 47.21% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $72.9 million, down from $89.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $130.3 million in Q3 2022, with the low at -$130.3 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $46.1 million (2025), against an average of $47.2 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments plunged 123.84% in 2023, then surged 326.98% in 2024.
• Monte Rosa Therapeutics' Change in Acquisitions & Divestments stood at -$130.3 million in 2022, then soared by 191.84% to $119.7 million in 2023, then sank by 68.87% to $37.2 million in 2024, then soared by 139.91% to $89.4 million in 2025, then dropped by 18.46% to $72.9 million in 2026.
• Business Quant data shows GLUE's Change in Acquisitions & Divestments at $72.9 million in Q1 2026, $89.4 million in Q4 2025, and $104.8 million in Q3 2025.